VIVJOA® (oteseconazole) is a prescription medication that has been recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of recurrent vulvovaginal candidiasis (RVVC) in women who are not pregnant and not able to become pregnant. RVVC is a condition characterized by frequent yeast infections that keep coming back despite treatment.

The main ingredient in VIVJOA® is oteseconazole, which belongs to the azole class of antifungal medications. It works by inhibiting the synthesis of ergosterol, which is a vital component of the fungal cell membrane, thereby preventing the growth and spread of Candida fungi that cause yeast infections.

RVVC can have a significant impact on a woman’s quality of life, including discomfort, pain, and interference with sexual activity. VIVJOA® offers a new option for women who suffer from RVVC and have not achieved relief with other treatment options.

Clinical trials have shown that VIVJOA® is highly effective in reducing the frequency of RVVC in women. In a Phase III clinical trial, women with a history of frequent RVVC were treated with VIVJOA® or placebo for up to 48 weeks. The results showed that VIVJOA® significantly reduced the frequency of RVVC episodes compared to placebo. Moreover, the treatment was well-tolerated, and patients reported no serious adverse events.

The recommended dose of VIVJOA® is one suppository inserted vaginally once a week for up to six months, depending on the severity of the RVVC. The suppository is easy to use and is inserted using a disposable applicator, which is included in the medication package.

The potential side effects of VIVJOA® are generally mild and include vaginal itching, burning, and irritation at the application site. In rare cases, more severe side effects, such as rash or hives, may occur. If any of these side effects occur, patients should stop using the suppository immediately and contact their doctor.

VIVJOA® may interact with other medications, so patients should inform their doctor if they are taking any other medication, especially medications that are metabolized by the liver.

It is important to note that VIVJOA® is not recommended for use during pregnancy or while breastfeeding, as its safety and efficacy have not yet been established in these populations.

In conclusion, VIVJOA® offers a new treatment option for women suffering from recurrent vulvovaginal candidiasis. With its unique mechanism of action and mild side effect profile, VIVJOA® offers a new hope for women who have not achieved relief with other treatment options. Although VIVJOA® is largely well-tolerated, patients should be aware of the potential side effects and drug interactions and should discuss these with their doctor before starting treatment.